文献速递浆细胞疾病

17p缺失的高亚克隆比例与多发性骨髓瘤不良预后相关

High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.
PubMed 文献 · Blood · 2019-01-28

该研究在新诊断多发性骨髓瘤(NDMM)患者中应用统一细胞遗传学评估,发现del17p的癌克隆比例(CCF)递增与生存期缩短相关,并确定CCF阈值0.55;CCF≥0.55且存在TP53缺失/突变的患者无进展生存期和总生存期均显著更差,3个数据集Meta分析证实该阈值稳健。

要点

  • del17p的CCF递增与NDMM患者生存期缩短相关。
  • CCF阈值0.55在发现集和复制集中均稳健。
  • CCF≥0.55且存在TP53缺失/突变才可识别高危NDMM。

核心结论

  • del17p的CCF阈值0.55与TP53缺失/突变同时存在,才能识别携带del17p且预后不良的NDMM患者。

研究设计与样本

  • 在新诊断多发性骨髓瘤(NDMM)患者中应用统一细胞遗传学评估,并在发现集和复制集中确定CCF阈值0.55,另分析第三个全外显子测序数据集,并对3个数据集进行Meta分析。

主要发现

  • 按CCF阈值0.55分层后,高危患者(CCF≥0.55)较低危患者(CCF<0.55)预后显著更差:中位无进展生存期(PFS)14个月 vs 23.1个月,中位总生存期(OS)32个月 vs 76.2个月。
  • 全外显子测序数据分析显示,除超过del17p的CCF阈值外,TP53缺失/突变的存在是高危分层所必需的条件。
  • 3个数据集的Meta分析证实CCF阈值对PFS和OS的稳健性。
  • 分析表明荧光原位杂交和测序方法可识别TP53缺失、估计CCF,并确立CCF阈值0.55与TP53缺失同时存在对识别高危del17p携带NDMM患者的必要性。

关键数值与推荐

  • CCF阈值为0.55。
  • 高危患者中位PFS为14个月,低危患者为23.1个月;高危患者中位OS为32个月,低危患者为76.2个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Deletions of chromosome 17p (del17p) that span the TP53 gene are associated with poor outcome in multiple myeloma (MM), but the prognostic value of del17p cancer clonal fraction (CCF) remains unclear. We applied uniform cytogenetic assessments in a large cohort of newly diagnosed MM (NDMM) patients carrying varying levels of del17p. Incremental CCF change was associated with shorter survival, and a robust CCF threshold of 0.55 was established in discovery and replication data sets. After stratification on the 0.55-CCF threshold, high-risk patients had statistically significantly poorer outcomes compared with low-risk patients (median progression-free survival [PFS] and overall survival [OS], 14 and 32 vs 23.1 and 76.2 months, respectively). Analyses of a third data set comprising whole-exome sequencing data from NDMM patients identified presence of TP53 deletions/mutations as a necessary requirement for high-risk stratification in addition to exceeding the del17p CCF threshold. Meta-analysis conducted across 3 data sets confirmed the robustness of the CCF threshold for PFS and OS. Our analyses demonstrate the feasibility of fluorescence in situ hybridization- and sequencing-based methods to identify TP53 deletions, estimate CCF, and establish that both CCF threshold of 0.55 and presence of TP53 deletion are necessary to identify del17p-carrying NDMM patients with poor prognosis.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Thakurta A, Ortiz M, Blecua P, et al. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. Blood. 2019. PMID: 30692124. doi:10.1182/blood-2018-10-880831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。